Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence (<0.75 ng/ml/year) from distant metastasis (> 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.
- Prostate specific antigen
ASJC Scopus subject areas